Adarza Biosystems Inc.’s Ziva platform can simultaneously detect hundreds of proteins, antibodies, or substrates from a single drop of blood, plasma or serum, providing insight into an individual’s immune response. That could be critical for both surveillance and diagnostic purposes as the nation prepares for a likely second wave of the novel coronavirus in the fall when multiple respiratory pathogens will be circulating.
Adarza BioSystems said the funding will help it prepare for commercialization of its ZIVA platform, a biological testing device designed to assist researchers with disease profiling and drug development.
Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.
Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development
Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3x5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney. Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.
Adarza Biosystems, Inc. announced today that it will reveal its new protein multiplex instrument ZIVA at Immunology 2019, the annual meeting of the American Association of Immunologists (AAI) from May 9 - 13. Using a simple, time-saving workflow, the new automated system can simultaneously measure, analyze and report on up to 200 biomarkers.
Agreement gives Horizon exclusive right to supply services on Ardaza’s multiplex label-free immunoassay technology.
Once Adarza's products launch in the second quarter of 2019, it will be one of a handful of local life sciences startups to have done so.
Adarza Biosystems, Inc., a biotechnology company developing a novel protein and biomolecule detection platform, announced today that it has put in place the leadership, new manufacturing center and branding to begin selling its technology to researchers in the second quarter of 2019.
As Adarza scales up, St. Louis hopes for an important win. By David Nicklaus
RiverVest leads $17 million investment in Adarza, brings on new president